Press coverage about Sol Gel Technologies (NASDAQ:SLGL) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sol Gel Technologies earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.9885897324391 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

NASDAQ:SLGL traded up $0.14 on Tuesday, reaching $6.43. 4,400 shares of the stock traded hands, compared to its average volume of 33,171. The firm has a market cap of $119.02 million and a P/E ratio of -1.28. Sol Gel Technologies has a 12 month low of $6.03 and a 12 month high of $16.48.

Sol Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.05 million. sell-side analysts anticipate that Sol Gel Technologies will post -1.97 EPS for the current fiscal year.

A number of analysts have weighed in on SLGL shares. Zacks Investment Research lowered shares of Sol Gel Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, May 19th. HC Wainwright started coverage on shares of Sol Gel Technologies in a research note on Monday, July 16th. They set a “buy” rating and a $21.00 price objective for the company. Finally, ValuEngine upgraded shares of Sol Gel Technologies from a “hold” rating to a “buy” rating in a research note on Monday, August 20th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $19.00.

Sol Gel Technologies Company Profile

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Further Reading: Trading Strategy

Insider Buying and Selling by Quarter for Sol Gel Technologies (NASDAQ:SLGL)

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with's FREE daily email newsletter.